Unveiling ResMed (RMD) Q1 Outlook: Wall Street Estimates for Key Metrics

Analysts on Wall Street project that ResMed (RMD) will announce quarterly earnings of $2.03 per share in its forthcoming report, representing an increase of 23.8% year over year. Revenues are projected to reach $1.19 billion, increasing 7.9% from the same quarter last year.The consensus EPS estimate for the quarter has undergone an upward revision of 0.5% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.Bearing this in mind, let's now explore the average estimates of specific ResMed metrics that are commonly monitored and projected by Wall Street analysts.Analysts forecast 'Global revenue- Devices' to reach $594.99 million. The estimate indicates a year-over-year change of +5.4%.The consensus among analysts is that 'Global revenue- Software as a Service' will reach $163.09 million. The estimate indicates a year-over-year change of +17.1%.Analysts' assessment points toward 'Global revenue- Total Sleep and Respiratory Care' reaching $1.02 billion. The estimate points to a change of +6.1% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Global revenue- Masks' of $426.53 million. The estimate indicates a year-over-year change of +7.1%.Analysts expect 'U.S., Canada, and Latin America- Devices' to come in at $366.97 million. The estimate points to a change of +6.1% from the year-ago quarter.Analysts predict that the 'U.S., Canada, and Latin America- Masks' will reach $311.67 million. The estimate indicates a change of +6.6% from the prior-year quarter.It is projected by analysts that the 'Combined Europe, Asia, and other markets- Total Sleep and Respiratory Care' will reach $342.88 million. The estimate suggests a change of +5.6% year over year.According to the collective judgment of analysts, 'Combined Europe, Asia, and other markets- Devices' should come in at $228.02 million. The estimate points to a change of +4.2% from the year-ago quarter.Based on the collective assessment of analysts, 'Combined Europe, Asia, and other markets- Masks' should arrive at $114.86 million. The estimate indicates a change of +8.6% from the prior-year quarter.The consensus estimate for 'U.S., Canada, and Latin America- Total' stands at $678.63 million. The estimate points to a change of +6.3% from the year-ago quarter.View all Key Company Metrics for ResMed here>>>Over the past month, ResMed shares have recorded returns of -2% versus the Zacks S&P 500 composite's +4.5% change. Based on its Zacks Rank #2 (Buy), RMD will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ResMed Inc. (RMD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks